Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs
June 26 2019 - 7:00AM
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader
in gene and cell therapy, today announced the appointment of Victor
Paulus, Ph.D. as Senior Vice President, Regulatory Affairs. The
Company also announced the appointment of Jodie Gillon, M.P.H. as
Vice President of Patient Advocacy and Clinical Affairs. Both Dr.
Paulus and Ms. Gillon are reporting to Chief Executive Officer João
Siffert, M.D.
“The addition of these seasoned industry leaders
will strengthen our relationships with key stakeholders toward the
successful development of our therapies,” said Dr. Siffert. “Victor
will lead us through the evolving regulatory landscape in close
collaboration with the development, CMC, and quality teams as we
close in on near-term milestones and prepare to bring new gene and
cell therapies to patients. He has a proven track record of shaping
preclinical and clinical regulatory strategies and securing product
approvals.”
“Jodie brings a unique blend of knowledge, broad
experience and empathy to reference as she leads patient advocacy
and clinical affairs for Abeona. Her qualifications are critical as
we advance the development of potentially transformative therapies
for serious rare diseases in close collaboration with patients and
their families, and internal and external medical and scientific
stakeholders,” added Dr. Siffert.
Dr. Paulus has over 30 years of experience in
the pharmaceutical industry, including over 20 years specializing
in Regulatory Affairs. Prior to joining Abeona, he served as Vice
President and Global Head of Regulatory Affairs at the
clinical-stage immunotherapy company Hookipa Pharma. Previously,
Dr. Paulus was Global Head of Regulatory Affairs for Advanced
Accelerator Applications, a Novartis Company, where he secured
orphan designations and product approvals for Gallium Ga68 dotatate
and Lutetium Lu177 dotatate. Earlier in his career, Dr. Paulus
served as Director of Regulatory Affairs for Pediatric Vaccines at
GlaxoSmithKline and Senior Director of Regulatory Affairs for
Biosimilar drug development at Dr. Reddy’s. He also held roles of
increasing responsibility at Organon, Elusys Therapeutics, and the
Population Council. Dr. Paulus began his career as a laboratory
technician at the Salk Institute manufacturing vaccines for the US
Army and then managed a cell culture laboratory at Centocor and
viral vaccine production at what is now Sanofi Pasteur. He was also
Manager of Regulatory Affairs for MCM (Merck-Connaught-Merieux),
developing novel combination pediatric vaccines. Dr. Paulus has BSc
degrees in Biology and Biochemistry, an MSc in biology
(parasitology) and a Ph.D. in public health.
Ms. Gillon has more than 20 years of industry
experience in various roles across Development, Medical and
Corporate Affairs. Prior to joining Abeona, she cumulatively spent
over a decade with Pfizer as the Global Medical Lead for Patient
Engagement within the Rare Diseases Business Unit and the Director
of Medical Communications within the Chief Medical Office. In these
roles, Ms. Gillon facilitated collaborations with patient groups
across many therapeutic areas and served as a core member of
several cross-functional teams. Prior to Pfizer, she was the Head
of Patient Advocacy and Professional Affairs with Achillion
Pharmaceuticals. Ms. Gillon also previously served as the Head of
the Chief Medical Office of AstraZeneca, which was preceded by
additional roles at Novartis and Oridion. She holds a M.P.H. with a
dual degree in Health Economics and Epidemiology from Hebrew
University in Jerusalem and a BSFS from Georgetown’s School of
Foreign Service.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing gene and cell therapies for serious diseases.
The Company’s clinical programs include EB-101, its autologous,
gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene
therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS
IIIB), respectively. The Company’s portfolio of AAV9-based gene
therapies also features ABO-202 and ABO-201 for CLN1 disease and
CLN3 disease, respectively. Its preclinical assets include ABO-401,
which uses the novel AIM™ AAV vector platform to address all
mutations of cystic fibrosis. Abeona has received numerous
regulatory designations from the FDA and EMA for its pipeline
candidates and is the only company with Regenerative Medicine
Advanced Therapy designation for two candidates (EB-101 and
ABO-102). For more information, visit
www.abeonatherapeutics.com.
Forward Looking Statement This press release
contains certain statements that are forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
and that involve risks and uncertainties. These statements
include statements about the ability of its management team to lead
the Company and deliver on key strategies, the market opportunities
for the Company’s products and product candidates, and the
Company’s goals and objectives. We have attempted to identify
forward looking statements by such terminology as “may,” “will,”
“anticipate,” “believe,” “estimate,” “expect,” “intend,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances), which
constitute and are intended to identify forward-looking statements.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, numerous risks and uncertainties, including but not
limited to continued interest in our rare disease portfolio, our
ability to enroll patients in clinical trials, the impact of
competition, the ability to secure licenses for any technology that
may be necessary to commercialize our products, the ability to
achieve or obtain necessary regulatory approvals, the impact of
changes in the financial markets and global economic conditions,
risks associated with data analysis and reporting, and other risks
as may be detailed from time to time in the Company’s Annual
Reports on Form 10-K and quarterly reports on Form 10-Q and other
reports filed by the Company with the Securities and Exchange
Commission. The Company undertakes no obligation to revise
the forward-looking statements or to update them to reflect events
or circumstances occurring after the date of this presentation,
whether as a result of new information, future developments or
otherwise, except as required by the federal securities laws.
Investor Contact:Sofia Warner Senior Director,
Investor Relations Abeona Therapeutics +1 (646) 813-4707
swarner@abeonatherapeutics.com
Media Contact:Scott Santiamo Director,
Corporate Communications Abeona Therapeutics +1 (718) 344-5843
ssantiamo@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2024 to May 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From May 2023 to May 2024